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Abstract
Background: Raf Kinase Inhibitory Protein (RKIP, also PEBP1), a member of the Phosphatidylethanolamine Binding Protein
family, negatively regulates growth factor signaling by the Raf/MAP kinase pathway. Since an organic compound, locostatin,
was reported to bind RKIP and inhibit cell migration by a Raf-dependent mechanism, we addressed the role of RKIP in
locostatin function.
Methods/Findings: We analyzed locostatin interaction with RKIP and examined the biological consequences of locostatin
binding on RKIP function. NMR studies show that a locostatin precursor binds to the conserved phosphatidylethanolamine
binding pocket of RKIP. However, drug binding to the pocket does not prevent RKIP association with its inhibitory target,
Raf-1, nor affect RKIP phosphorylation by Protein Kinase C at a regulatory site. Similarly, exposure of wild type, RKIP-
depleted HeLa cells or RKIP-deficient (RKIP
2/2) mouse embryonic fibroblasts (MEFs) to locostatin has no effect on MAP
kinase activation. Locostatin treatment of wild type MEFs causes inhibition of cell migration following wounding. RKIP
deficiency impairs migration further, indicating that RKIP protects cells against locostatin-mediated inhibition of migration.
Locostatin treatment of depleted or RKIP
2/2 MEFs reveals cytoskeletal disruption and microtubule abnormalities in the
spindle.
Conclusions/Significance: These results suggest that locostatin’s effects on cytoskeletal structure and migration are caused
through mechanisms independent of its binding to RKIP and Raf/MAP kinase signaling. The protective effect of RKIP against
drug inhibition of migration suggests a new role for RKIP in potentially sequestering toxic compounds that may have
deleterious effects on cells.
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Introduction
Raf Kinase Inhibitory Protein (RKIP) is an inhibitor of key
signal transduction cascades in mammalian cells that regulate
growth and differentiation (reviewed in [1,2]). RKIP binding to
Raf-1 prevents MAP kinase signaling in response to growth factors
[3]. Following stimulation of growth factor receptors, RKIP is
phosphorylated at Ser-153 by protein kinase C (PKC), enabling
RKIP dissociation and subsequent phosphorylation of Raf-1 at
activating sites [4,5]. RKIP binding to G-protein coupled receptor
kinase 2, a kinase that phosphorylates and downregulates G-
protein-coupled receptors, causes up-regulation of G protein-
coupled receptors such as the b-adrenergic receptor [6]. RKIP has
also been shown to bind NF-kB-inducing enzyme, NIK and
inhibit signaling mediated by NF-kB [7]. Finally, RKIP regulates
the spindle checkpoint through inhibition of the MAP kinase
cascade [8]. RKIP is also missing or depleted in a number of
metastatic tumors (reviewed in [1]), and has been implicated as a
metastasis suppressor through regulation of one or more of these
signaling cascades [9,10].
RKIP, also termed phosphatidylethanolamine binding protein-
1 (PEBP-1), is a 20–25 kDa globular protein that belongs to the
PEBP family comprised of over 400 members. The crystal
structures of PEPBs from bacteria to humans have revealed a
remarkably conserved ligand-binding pocket [1]. In these crystal
structures, phosphorylethanolamine as well as other ions are found
in the ligand-binding pocket [11], and the pocket has been shown
to bind hydrophobic ligands such as phospholipids [12]. While
other ligands have also been reported to bind RKIP, the specific
ligands that bind RKIP at physiological pH are yet to be defined.
Since RKIP regulates key physiological processes, it is of interest
for therapeutic purposes to identify agents that either prevent or
potentiate its ability to inhibit target proteins such as Raf-1.
Recently, locostatin ((S)-(+)-4-benzyl-3-crotonyl-2-oxazolidinone)
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6028was shown to bind to RKIP and inhibit migration of Madin-Darby
canine kidney (MDCK) epithelial cells [13,14]. In this cell type,
RKIP depletion also inhibited migration. Consistent with a role in
Raf signaling, locostatin prevented co-immunoprecipitation of
RKIP with Raf-1 in vitro. Overexpression of RKIP in these cells
reversed the anti-migratory effect of locostatin and cells adopted a
fibroblast-like phenotype [13]. More recently, locostatin was also
observed to impair migration in another cell type, human breast
adenocarcinoma (MCF7), as well as causing these cells to have
poor cell-cell adhesive properties [14]. These results suggest that
locostatin regulates cell migration via an RKIP-dependent, Raf/
MAPK-regulated mechanism.
To address the role of RKIP in locostatin function, we analyzed
locostatin interaction with RKIP and the biological consequences
of locostatin treatment in both human and murine cell types. Our
results suggest that locostatin interacts with the RKIP ligand-
binding pocket but its effects on the cytoskeleton, mitotic spindle,
and cell migration are independent of RKIP and the MAP kinase
signal transduction cascade. Instead, RKIP appears to rescue cells
from inhibition of migration by locostatin, raising the possibility
that RKIP may function in part to sequester deleterious drugs.
Results
Locostatin precursor binds to the ligand binding pocket
of RKIP
To define the RKIP binding site for locostatin, we analyzed
their interaction by NMR. We found that locostatin, a suicide
inhibitor that irreversibly attached itself to RKIP, had limited
solubility, and addition of locostatin to an NMR sample containing
100 mM RKIP caused RKIP precipitation, rendering NMR
characterization of the RKIP-locostatin complex impossible.
However, a precursor of locostatin that had the same basic
structure but lacked the reactive crotonyl group, (S)-4-benzyl-2-
oxazolidinone (Fig. 1A), was compatible with NMR studies. To
detect perturbations caused by precursor binding at a single amino
acid residue resolution, we obtained
1H,
15N single-quantum
correlation spectra (HSQC) in which each cross peak representing
a directly bonded
1H-
15N pair functions as an amide-specific
probe in
15N-enriched proteins [15,16]. Since we previously
obtained the complete sequence-specific resonance assignments of
backbone amides for wild-type RKIP [16], this approach enabled
us to relate any perturbed HSQC cross peaks to a specific residue
within RKIP. A comparison of HSQC spectra of wild-type RKIP
in the presence or absence of the locostatin precursor (Fig. 1B)
revealed that a majority of peaks affected by ligand binding were
associated with the ligand-binding pocket (Fig. 1C). The entire
rim of the pocket as well as the C-terminal alpha helix were
perturbed, and the strongest perturbations seem to cluster near the
C-terminal alpha helix and the conserved P74 residue on the
opposite face. However, there are almost no perturbations in the
region of S153, the site that, when phosphorylated, prevents RKIP
binding to Raf [4,12]. These results indicate that a locostatin-
related compound indeed binds RKIP and occupies the
evolutionarily conserved ligand-binding pocket of RKIP. Given
the structural similarity, these results strongly suggest that
locostatin also binds to the RKIP ligand-binding pocket.
Locostatin does not alter RKIP binding to Raf-1
Initially we determined whether locostatin affects cellular RKIP
association with Raf-1 either directly or indirectly via regulation of
RKIP phosphorylation at S153. To test whether locostatin inhibits
RKIP binding to Raf-1, we immunoprecipitated TAP-Raf-1
(Tandom Affinity Purification using Protein A and Flag-tagged
Raf-1) that was stably expressed in H19-7 cells. The TAP-Raf-1
bound to beads was incubated with soluble, bacterially expressed
RKIP in the presence of increasing concentrations of locostatin.
We have used this approach previously (confirmed in Fig. 2A)t o
show that 2-dihexanoyl-sn-glycero-3-phosphoethanolamine
(DHPE), a water-soluble, short-chain analog of phosphatidyleth-
anolamine, binds to the RKIP pocket and competes with Raf-1 for
association [12]. However, in contrast to DHPE, locostatin up to a
concentration of 2.5 mM did not significantly inhibit RKIP
binding to Raf-1 (Fig. 2A).
It is also possible that locostatin binding to RKIP in cells alters
PKC phosphorylation of RKIP, thus indirectly affecting associa-
tion of RKIP with Raf-1. To test this possibility, we determined
the effect of different locostatin concentrations on RKIP
phosphorylation at S153 by PKC using an in vitro kinase assay.
Again, in contrast to DHPE [12], locostatin had no effect on RKIP
phosphorylation at S153 even at higher drug concentrations
(Fig. 2B). Taken together, these results indicate that locostatin
binding to RKIP does not significantly alter RKIP binding to its
inhibitory target, Raf-1.
Locostatin does not inhibit ERK
We have previously shown that depletion of RKIP in HeLa cells
enhances the amplitude of the ERK signal induced by epidermal
growth factor (EGF) stimulation [5]. Since locostatin does not
prevent RKIP association with Raf, then locostatin treatment of
cells should not effect ERK signaling. Therefore, to investigate the
role of locostatin in MAPK signaling, we pretreated control and
RKIP-depleted HeLa cells with 20 or 50 mM locostatin for
30 min, a concentration range that was previously shown to
inhibit cell migration [17]. Cells were then stimulated with EGF
(10 ng/ml) in the final five minutes of incubation. As predicted, we
observed a 2 to 3-fold increase in MAPK activity (measured as a
ratio of phospho-ERK to total ERK) in depleted RKIP cells
compared to control cells (Fig. 3A and B). Locostatin (20 or
50 mM) had no effect on basal levels of MAPK activity in these
cells (Fig. 3). Similarly, locostatin failed to impair or enhance the
EGF-induced MAPK activity independent of RKIP expression.
An inactive analogue of locostatin that cannot bind RKIP,
UIC1017 [17] also had no effect on EGF-induced MAPK activity
in these cells (data not shown).
To further confirm that any locostatin effects on cells are
independent of RKIP or MAPK activation status, we also tested
the effect of locostatin on mouse embryonic fibroblasts (MEFs)
isolated from either wild type (RKIP
+/+) or homozygous (RKIP
2/
2) mice. As observed with HeLa cells, neither 20 mM nor 50 mM
locostatin had any effect on EGF-induced MAPK activity in MEFs
that express or are deficient in RKIP (Fig. 3C–F). These results
indicate that locostatin binding to the RKIP ligand pocket does
not perturb RKIP/Raf-1 association nor alter MAPK activity.
RKIP protects against locostatin inhibition of cellular
migration after wound healing in MEFs
Previous reports using MDCK and MCF-7 cells have shown
that 50 mM locostatin inhibits the rate of cell migration of cultured
cells following wounding [14]. To determine whether locostatin
inhibits migration in another cell type, we established a scratch
wound assay using RKIP
+/+ MEFs (Fig. 4). MEFs were treated
with DMSO (vehicle control) or two different doses of locostatin
and the wounds were visualized using digital images at 0, 4, 8 and
24 h time points. In the presence of vehicle (0.25% DMSO), the
cells healed within 24 h (Fig. 4A) with no signs of cell toxicity as
determined by trypan blue exclusion (data not shown). Similarly,
20 mM locostatin had no effect on migration (Fig. 4A), as opposed
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PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e6028Figure 1. Binding of the locostatin precursor (S)-4-benzyl-2-oxazolidinone (Sigma #294640) to RKIP characterized by NMR
chemical shift perturbation. (A) Chemical structure of locostatin and its precursor (S)-4-benzyl-2-oxazolidinone. (B) Comparison of
1H,
15N-HSQC
spectra of
15N-enriched RKIP in the absence-black and the presence-red of the compound (1 mM). Each cross peak (dot) represents the correlation
between the directly bonded amide
1H and
15N atoms of amino acid residue. (C) The locations of amino acid residues whose HSQC peak is
significantly affected by compound binding mapped on the RKIP structure. Red, yellow and gray spheres represent residues that have the weighted
shift of .0.3 ppm, 0.2. ppm and .0.1 ppm, respectively.
doi:10.1371/journal.pone.0006028.g001
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PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e6028Figure 2. DHPE but not locostatin decreases RKIP interactions with Raf-1 and PKC. (A) RKIP association with Raf-1 in the presence or
increasing concentrations of locostatin or DHPE. Upper panels: Representative western blots. Lower panels: Bar graphs representative of two
independent experiments6range. (B) PKC phosphorylation of RKIP in the presence of increasing concentrations of locostatin or DHPE using RKIP or
MBP as substrates. Upper panels: Representative autoradiogram is shown. Lower panels: Bar graphs representative of two independent
experiments6range.
doi:10.1371/journal.pone.0006028.g002
Locostatin Impairs Migration
PLoS ONE | www.plosone.org 4 June 2009 | Volume 4 | Issue 6 | e6028Locostatin Impairs Migration
PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e6028to 50 mM locostatin which impaired wound healing at all time
points measured (Fig. 4B). Locostatin (50 mM) when compared to
vehicle (0.25% DMSO) treatment (24 h time point) reduced
migration by 4065% (n=8 separate wounds) in RKIP
+/+ MEFs
(Fig. 4B). Surprisingly, depletion of RKIP (depletion described
here refers to short-hairpin RNA interference with RKIP in
MEFs) further reduced migration to 7763% at this concentration
of locostatin (Fig. 4D). To confirm that remaining RKIP in the
depleted MEFs was not responsible for the observed effects, we
also tested RKIP deficient MEFs (RKIP
2/2). Total loss of RKIP
almost completely inhibited migration in the presence of 50 mM
locostatin, 9665% at 24 h when compared to RKIP
+/+;p ,0.01;
compare Fig. 5B and D). Furthermore, the rate of migration in
the presence of vehicle was not significantly affected by the
presence or absence of RKIP. Therefore, these results indicate that
50 mM locostatin is sufficient to inhibit migration, and RKIP
confers significant protection to cells within this concentration
range.
Locostatin impairs cytoskeletal organization, disrupts the
mitotic spindle and promotes nuclear fragmentation
Since locostatin has been previously reported to inhibit cell
migration, its physiological effects are likely mediated, at least in
part, via cytoskeletal interactions. To investigate the cytoskeleton
we pretreated MEFs of varying genotypes with locostatin (50 mM)
and stained them with phalloidin to locate actin filaments within
the cell. Previous studies [17] reported that locostatin did not affect
the formation of new filamentous actin bundles in MDCK cells
post wounding. By contrast, we observed a time dependent
induction of cytoskeletal reorganization by locostatin in MEFs
(Fig. 6).InvehiclecontrolMEFs(RKIP
+/+,d e p l e t e da n dR K I P
2/2),
cells stained positive for filamentous F-actin with an even distribution
of F-actin around the nucleus as well as along stress fibers within the
cell (Fig. 6). In the presence of locostatin (50 mM) we observed a
slight decrease in actin staining after 2 h of treatment, and by 6 h
actin was predominantly localized to the perinuclear region of the cell
(Fig. 6). Similarly, RKIP depleted cells displayed a locostatin effect;
however, by 6 h it was evident that locostatin caused the collapse of
the cytoskeleton as evidenced by near absent actin staining
throughout the cell (Fig. 6). Likewise, locostatin caused reduced
actin staining in RKIP deficient (RKIP
2/2)M E F s( Fig. 6,l o w e r
panel). As observed with migration, the effect of locostatin was more
pronounced in RKIP
2/2 MEFs compared to RKIP
+/+.B y6h ,
treatment with locostatin in all genotypes exhibited disrupted actin
cytoskeleton as detected by phalloidin. However, following 2 h
treatment with locostatin the RKIP
+/+ cells looked similar to vehicle
control cells, whereas the RKIP depeleted or RKIP
2/2 cells already
displayed defects in the actin cytoskeleton. Thus, RKIP appears to
transiently protect cells from locostatin mediated disruption of the
actin cytoskeleton.
The mitotic spindle is composed of microtubules that are highly
sensitive to both polymerizing and depolymerizing agents, and
therefore could serve as a sensor for microtubule-dependent
cytoskeletal changes. To test this possibility, we determined
whether locostatin affects mitotic spindle structure. RKIP
+/+
MEFs or RKIP-depleted MEFs were either untreated or treated
with locostatin (20 mM) for the indicated time (Fig. 7A) and cells
were fixed and stained with anti-a tubulin antibody. As shown in
Fig. 7A locostatin caused a time dependent loss of spindle fiber
tension in RKIP
+/+ and RKIP-depleted cells. Both RKIP
+/+ and
RKIP
2/2 MEFs were treated for 6 h with locostatin (20 mM)
which showed defects in mitotic spindle formation and chromo-
some organization (Fig. 7B). Although abnormal spindles were
observed after 2 h treatment with 20 mM locostatin in all cell
types, there were fewer abnormal spindles following 1 h treatment
in RKIP expressing cells (supplemental Fig. S1). We also observed
at this dose of locostatin a disruption in chromatin condensation in
a manner reminiscent of Taxol, a drug that causes loss of spindle
fiber tension (Fig. 7B). This effect was independent of RKIP
expression, indicating that locostatin targets cytoskeletal elements
through a mechanism that does not involve RKIP binding or
inhibition of RKIP function.
Discussion
In this study, we have demonstrated that locostatin inhibits
migration in MEFs independent of RKIP expression and Raf/
MAPK signaling. The locostatin precursor binds to RKIP’s
ligand-binding pocket but has no effect on Ser-153, the known site
for PKC phosphorylation of RKIP that leads to dissociation of
RKIP from Raf-1 [4]. Similarly, increasing concentrations of
locostatin and its precursor had very little effect on RKIP
phosphorylation by PKC or RKIP/Raf-1 association. Finally,
locostatin in RKIP-depleted and RKIP-deficient cell lines (HeLa
and MEFs) had no effect on the EGF-induced activity of MAPK, a
downstream signaling target of Raf. Furthermore, our data shows
that locostatin is not specific to RKIP and has off target effects. In
particular, locostatin reorganizes the actin cytoskeleton, disrupts
the mitotic spindle and inhibits cell migration via a mechanism
that is independent of the MAPK pathway. The protective effect
of RKIP toward locostatin disruption of the cytoskeleton and
inhibition of migration indicates that RKIP can influence
locostatin action but not necessarily as a mediator. Our results
raise the possibility that RKIP may function to trap locostatin,
sequestering the toxic drug within the cell.
Our results add a different perspective to our understanding of
locostatin interaction with RKIP. Previous studies have shown that
locostatin prevents RKIP from co-precipitating with Raf-1.
However, it is possible that the chemically reactive nature of
locostatin may have caused other interactions that sterically hinder
Raf access to RKIP. The deleterious effects of locostatin on
cytoskeletal structures and cell migration even in cells lacking
RKIP suggest that locostatin has other targets that may not have
been previously identified. One puzzling observation is that
locostatin inhibits spindle organization and cell migration at 20–
50 mM but the precursor binds to RKIP at millimolar concentra-
tions. The reduced apparent affinity of the precursor may be
attributable to the different modes of interaction between the two
compounds. Locostatin acts as a suicide inhibitor that covalently
attaches itself to RKIP, while the precursor lacks a chemically
reactive group and binds RKIP in a reversible manner [13]. An
alternative explanation for these differences may be the size of
locostatin compared to its precursor, which may also cause
Figure 3. Locostatin has no effect on EGF-induced MAPK activity. (A, B) HeLa cells expressing control or depleted RKIP or (C, D) MEFs
expressing wild-type RKIP (RKIP
+/+)o r(E, F) MEFs not expressing RKIP (RKIP
2/2) were serum starved overnight and then pre-treated for 30 min with
DMSO or locostatin (concentrations as indicated). EGF (10 ng/ml) was added in the final 5 minutes of incubation. Whole cell lysates (30 mg) were
separated on SDS-PAGE gels (12.5%), transferred to nitrocellulose and analysed by immunoblotting with anti-phospho ERK and anti-total ERK
antibodies (A, C and E). ERK phosphorylation was assessed by normalizing phospho-ERK levels to total ERK levels as depicted in bar graphs (B, D
and F). The results shown are representative of three independent experiments.
doi:10.1371/journal.pone.0006028.g003
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PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e6028Figure 4. Locostatin impairs wound healing in wild-type and depleted RKIP MEFs. MEFs expressing wild-type (A, B) or depleted (C, D)
RKIP were seeded at 0.5610
6/ml and grown for 24 h before treatment with either DMSO (control) or locostatin at 20 (A) and (C) or 50 mM (B) and
(D). (E) A standardized scratch (wound) was applied to monolayers and digital images were taken at time points indicated. Cell migration was
determined as described in materials and methods. Data represents the mean6SEM of eight wounds from two independent experiments.
*p,0.05,
**p,0.01 indicates the significance of the change relative to the corresponding sample in the absence of locostatin.
doi:10.1371/journal.pone.0006028.g004
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PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e6028Figure 5. Locostatin impairs wound healing independent of RKIP. MEFs expressing wild-type (A, B) or deficient (C, D) RKIP were seeded at
0.5610
6/ml and grown for 24 h before treatment with either DMSO (control) or 20 (A) and (C) or 50 mM (B) and (D) locostatin. (E) A standardized scratch
(wound) was applied to monolayers and analyzed as in materials and methods. Data represents the mean6SEM of three independent experiments (n=4
wounds/sample).
*p,0.05,
**p,0.01 indicates the significance of the change relative to the corresponding sample in the absence of locostatin.
doi:10.1371/journal.pone.0006028.g005
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PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e6028Figure 6. Locostatin impairs cytoskeletal organization independent of RKIP expression. MEFs expressing wild-type, depleted or no RKIP
were plated at 2610
4 cells/coverslip and grown for 48 h before treatment with either DMSO (Control) or locostatin (50 mM) for either 2 or 6 h. Cells
were fixed and permeabilized and stained with phalloidin for actin-red. DNA/chromatin was stained with Ho ¨echst 33342-blue. Digital
photomicrographs were captured using Openlab Darkroom (Improvision) and a Retiga 1300 color digital camera (Q Imaging). Images from MEFs
expressing wild-type RKIP were similar to the RKIP
+/+ MEFs which express lentiviral vector control. Intensity of images were adjusted to display
qualitative rather than quantitative comparisons so that the intensity of staining in each panel cannot be directly compared.
doi:10.1371/journal.pone.0006028.g006
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PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e6028Figure 7. Locostatin disrupts the mitotic spindle and chromosome organization. MEFs expressing (A) wild-type (RKIP
+/+) or lacking RKIP
were plated at 2610
4 cells/coverslip and grown for 48 h before treatment with either DMSO (Control) or locostatin (20 mM) for either 1 or 2 h. (B)
Wild-type (RKIP
+/+) or deficient (RKIP
2/2) RKIP were plated as described in (A) and treated with either DMSO (Control), locostatin (20 mM) or paclitaxel
(10 mM) for 6 h. Cells were fixed and permeabilized and stained with anti-a-tubulin antibody-green. DNA/chromatin was stained with Ho ¨echst 33342-
blue. Digital photomicrographs were captured using Openlab Darkroom (Improvision) and a Retiga 1300 color digital camera (Q Imaging). Intensity of
images were adjusted to display qualitative rather than quantitative comparisons so that the intensity of staining in each panel cannot be directly
compared.
doi:10.1371/journal.pone.0006028.g007
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unfortunaletly solubility constraints for the precursor limited our
study in an intact cell system. The effect of locostatin is highly
concentration-dependent; just a two-fold decrease in dose caused
loss of inhibition. Thus, a reduction of the effective concentration
of locostatin in cells could significantly diminish its efficacy. RKIP
may be present in the cell at sufficient concentrations to promote
RKIP-locostatin interaction and sequester the toxic drug.
Alternatively, it is also possible that RKIP plays a discrete role
in cytoskeletal organization and migration that counteracts the
effects of locostatin.
Cell migration is a key step underlying cellular development as
well as other physiological and disease processes but whether
RKIP plays a role in regulating this process is still unresolved. In
some studies, RKIP overexpression inhibits migration and
invasion [18,19]. In other reports, RKIP promotes cell migration
by downregulating E cadherin and upregulating b1 integrin
[13,14]. In the present study using MEFs, the presence or absence
of RKIP has no effect on the rate of wound healing. The inhibitory
action of locostatin on wound healing in the MEFs appears to be
associated with changes in the cytoskeleton. We stained cells of
varying RKIP genotypes for actin with phalloidin and observed
the shortening of stress fibers within the cytoplasm and a
concentration of actin around the nucleus. These were exacer-
bated in MEFs with depleted or absent RKIP and these cells had
an increased amount of nuclear bodies with very little actin
association compared to their wild-type counterparts. Similarly,
the inhibitory effect of locostatin on migration and cytoskeleton
was more pronounced when cells were grown to a lower density as
opposed to the confluent monolayers described by [17], and we
also observed interbatch variations of locostatin potency. Collec-
tively, these discrepancies may reflect differences in cell type and/
or assays and will require further analysis of multiple tissues from
RKIP knockout mice.
At the doses of locostatin used in this study, we have shown that
RKIP may not be the only locostatin target regulating cell
migration. Previously, [
3H]locostatin was shown in an association
assay to bind to four proteins only, one of which was RKIP [13].
The other proteins were omega 1-1, prolyl endopeptidase and
aldehyde dehydrogenase (ALDH1A1). However, they reported
that ALDH1A1, which belongs to the ALDH family of enzymes
and is known to clear the cell of toxic reactive oxygen species
byproducts predominantly in the liver [20], bound to locostatin
but was not involved in cell migration. Interestingly, ALDH1A1
was recently shown to mediate cell invasion in pancreatic cancer
cells [21] suggesting that it does play a role in cytoskeletal
rearrangement. Therefore, these results raise the question whether
ALDH1A1 might function to bind locostatin as a toxic byproduct
for its removal from the cell. If this were true, ALDH1A1 function
would complement a role for RKIP in binding to locostatin to
mop up the drug and subsequently dampen its anti-migratory
effect on the cell.
To our knowledge this report provides the first evidence that
locostatin can alter both microtubule (tubulin) and actin-based
cytoskeletal elements. We observed that locostatin interferes with
the cytoskeleton of MEFs since it caused the collapse of the actin
cytoskeleton within the cell and localized actin to perinuclear
regions. Locostatin also disrupted mitotic spindle formation in
MEFs similar to the effects of Taxol. These results suggest that
locostatin plays a role in altering the cytoskeleton via a yet to be
defined mechanism warranting future investigation.
The present study of locostatin binding to RKIP also provides
insight into the role of the pocket in Raf-1 interactions. The
precursor bound directly to the pocket as shown by the
perturbation of key residues in the RKIP ligand binding pocket.
Although locostatin’s binding to RKIP could not be examined
directly by NMR due to its aggregation at high concentrations, it is
likely that locostatin binds to the same RKIP pocket residues. The
data show precursor binding to the RKIP pocket is not sufficient to
interfere with Raf binding, consistent with the observed MAPK
signaling in locostatin-treated cells. This result is in contrast to the
lipid DHPE that not only binds the pocket but also inhibits RKIP-
Raf association. Comparison of these different outcomes suggests
that other residues and/or steric features of RKIP as well as size of
the ligand are critical for Raf-1 binding [12].
RKIP is a negative regulator of major signaling cascades
including MAPK; therefore, the identification of drugs that bind to
RKIP and influence its inhibitory function could represent an
important therapeutic strategy. Although locostatin is the first
described drug to bind RKIP, it is likely that other chemicals also
interact with RKIP via the ligand binding pocket. The studies here
suggest that it may be possible to find therapeutic agents that
either potentiate or suppress RKIP association with kinases and its
inhibitory targets. Further studies to characterize the nature of the
interactions will be needed to identify the most effective RKIP-
modulating drugs. This work also suggests that RKIP might serve
as a ‘‘reservoir’’ for hydrophobic chemicals circulating in the
blood.
Materials and Methods
Reagents and antibodies
(S)-(+)-4-benzyl-3-crotonyl-2-oxazolidinone (locostatin) and its
precursor, (S)-4-benzyl-2-oxazolidinone (Fig. 1A) used in NMR
studies were from Aldrich (St. Louis, MO). Protease inhibitor
cocktails and locostatin unless otherwise indicated were from
Calbiochem. All cell culture media and supplements were from
GIBCO (Invitrogen, Carlsbad, CA).
15N-ammonium chloride was
from Cambridge Isotope Laboratories (Andover, MA). Anti-
phospho and -total ERK antibodies were from Cell Signaling
Technology (Beverly, MA). Anti-rabbit and –mouse IR dye
secondary antibodies as well as Odyssey blocking buffer used for
Western blotting were purchased from LI-COR Biosciences
(Lincoln, NE). Anti-a tubulin (B-7) mouse antibody was purchased
from Santa Cruz Technologies (Santa Cruz, CA). Anti-RKIP
antibody was developed as described [4]. FITC-conjugated
donkey anti-mouse secondary antibody was from Jackson
Immunolabs (West Grove, PA). Ho ¨echst 33342 nucleic acid stain
and Alexafluor 594-tagged phalloidin were from Molecular Probes
(Eugene, OR) and mounting media was Vectashield Hardset from
Vector Labs (Burlingame, CA). IgG sepharose beads were from
Amersham Biosciences (GE Healthcare, Piscataway, NJ). Biotiny-
lated thrombin (50 U) was from Novagen (Madison, WI).
Cell lines and cell culture
HeLa cells stably expressing short hairpin RNA vectors for
depleting human RKIP or rat RKIP control were maintained at
37uC/5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum, 50 U/ml penicillin
and 50 mg/ml streptomycin under puromycin (2 mg/ml) selection
as previously described [5]. Mouse embryonic fibroblasts (MEFs)
expressing varying genotypes of RKIP (wild-type RKIP
+/+ or
homozygous RKIP
2/2) were isolated from knockout RKIP mice
that were generated using embryonic stem cells established by the
Sanger Center using a gene targeting approach similar to that
previously described [22]. MEFs were isolated from 12.5-day-old
embryos that were derived from intercross of RKIP
+/2 mice. The
generation and characterization of RKIP knockout mice and
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temperature sensitive SV40 large T-antigen. RKIP
+/+ MEFs were
depleted by transduction with shRNA vectors using a pLKO.1
lentiviral vector as previously described [10]. These cells were
maintained in culture medium (as described for HeLa cells under
200 mg/ml geneticin and/or 2.5 mg/ml puromycin selection at
33uC/5% CO2.
NMR analysis
15N-Enriched RKIP was prepared by expressing the GST-
RKIP fusion protein in M9 minimal media supplemented with
15N-ammonium chloride. After purification, RKIP was excised
from the fusion protein using thrombin and concentrated. The
NMR sample contained 100 mM
15N-RKIP in 50 mM Tris HCl
buffer (pH 7.4) containing 100 mM NaCl prepared in 93% H2O
and 7% D2O.
1H,
15N-HSQC spectra were acquired at 30uCo na
Varian Inova 600 spectrometer equipped with a cryogenic probe.
NMR data were processed using the NMRPipe suite [23] and
analyzed using the NMRView program [24]. Sequence-specific
resonance assignments for RKIP have been published (BMRB
accession code 6783) [16]. The weighted shift, ((
1H
shift)
2+0.17(
15N shift)
2)
1/2, was calculated following the method
of Farmer et al. [25].
In vitro Raf and PKC kinase assay
The pRav-Flag-Raf-1 plasmid (TAP-Raf-1; Tandem Affinity
Purificationusing Protein A and Flag tagged-Raf-1)wasconstructed
as previously described [12] and stably expressed in H19-7 cells.
Briefly, TAP-Raf-1 was immunoprecipitated from H19-7 cells that
were serum starved overnight in DMEM media with no
supplements, and TAP-Raf was isolated on IgG sepharose beads.
Cellswere lysedinTAP-lysisbuffer(10 mMHEPESpH 7.4,3 mM
MgCl2, 10 mM KCl, 5% Glycerol, 0.1% NP40) and cleared by
centrifugation. Cell lysates were combined with pre-equilibrated
TAP-lysis buffer IgG sepharose beads and incubated for 1 h at 4uC.
Beads were washed with TAP-lysis buffer and equilibrated with
binding buffer (10 mM HEPES pH 7.4, 3 mM MgCl2,1 0m M
KCl, 150 mM NaCl). Beads were aliquoted and combined with
RKIP (5 mg) and increasing concentrations of locostatin or 1,2-
dihexanoyl-sn-glycero-3-phosphoethanolamine (DHPE).and incu-
bated for 30 min at 4uC. Complexes were washed three times with
binding buffer with corresponding concentrations of locostatin or
DHPE and boiled in sample buffer (26). Lysates were separated on
SDS-PAGE (12%), transferred to nitrocellulose and immunoblotted
with anti-RKIP antibody.
RKIP phosphorylation
In vitro phosphorylation of RKIP by PKCa was as previously
described [12]. Briefly, RKIP (5 mg) was combined with increasing
concentrations of locostatin or DHPE and the reaction was
initiated with 100 mM ATP containing 5 mCi of [c-
32P]ATP at
30uC for 10 min. The reaction was terminated using sample buffer
(66) and boiling at 100uC for 5 min. Lysates were separated on
SDS-PAGE (12%), transferred to nitrocellulose and visualized by
exposing to film. Results were quantified using phospho-imager
screens (Molecular Dynamics) and analyzed with ImageQuant
software. Membranes were subsequently immunoblotted with
anti-RKIP antibody [4].
MAPK activation assay
HeLa cells or MEFs (RKIP
+/+ or RKIP
2/2) were seeded in 6-
well plates at 0.5610
6/ml and allowed to adhere overnight at
37uCo r3 3 uC respectively [5,10]. Cells were serum starved
overnight in DMEM media with no supplements. The next day
cells were treated with DMSO (0.1 or 0.25%) or locostatin (20 or
50 mM) for 25 min followed by EGF (10 ng/ml) for 5 min at 37uC
or 33uC respectively. The reaction was terminated by placing
plates on ice and washing with cold PBS (containing protease
inhibitors). Cells were homogenized by cell scraping in RIPA lysis
buffer supplemented with sodium orthovanadate (0.1 mM),
sodium fluoride (0.5 mM) and protease inhibitor mixture tablet.
Cell lysates were sheared five times in a 1 ml tuberculin syringe
attached with a 21 G619 mm needle, left on ice for 1 h and then
spun at 16, 0006g for 10 min at 4uC. Cell lysates (30 mg) were
resolved by SDS-PAGE (12.5%), transferred to nitrocellulose and
analysed by Western blotting with anti-phospho ERK (Cell
Signaling Technology, Inc) or anti-total ERK (Cell Signaling
Technology, Inc) primary antibodies. Membranes were probed
with anti-rabbit and –mouse IR dye secondary antibodies (LI-
COR Biosciences). The amount of MAPK activity determined for
each sample was normalized to total ERK in each sample. Digital
analysis of immunoreactivity was done using LI-COR Biosciences
Infrared Imaging System which is quantitative and independent of
exposure time. Odyssey software (version 2.1; Lincoln, NE) was
used for analysis of the immunoblots.
Scratch wound assay
MEFs of varying genotypes (as indicated) were seeded at
0.5610
6/ml in 6-well plates under selection as described above
and allowed to adhere for 24 h at 33uC. On the day of the assay
wells were rinsed once with warm PBS and then kept in
supplemented DMEM media in the absence or presence of
DMSO (0.1 or 0.25%) or locostatin (20 or 50 mM) at 33uC for
24 h. Wounding was performed using a pipette tip and by drawing
four wounds of standard size across a confluent monolayer of cells.
Prior to incubation at 33uC/5% CO2, digital images were taken at
time zero followed by four, eight and 24 h. Images were taken on a
phase-contrast microscope (Leica DMIRB, epifluorescence) at 65
magnification. Wound area was determined as a percentage of the
wound size at time zero and using the area of the wound as
measured by Image J software (NIH). Initial wound area was
standardized for all conditions tested and then changes in area
over time were expressed as a percentage of the initial time zero
wound.
Actin localization and mitotic spindle microscopy
MEFs of varying genotypes (as indicated) were plated at 2610
4
cells per 15 mm coverslip and grown for 48 h. Cells were treated
with DMSO only (Control), or locostatin (20 or 50 mM), or
paclitaxel (10 mM) for 1 to 6 h (as indicated), followed by fixation
with 4% paraformaldehyde (in 0.1 M Na-phosphate, pH 7.4) for
10 mins at room temperature (RT), permeabilized with 0.1%
TritonX-100 in PBS for 2 mins at RT, and blocked with 3% BSA
in PBS overnight at 4uC. Alpha-tubulin was detected using a
mouse antibody at 1:50 dilution and actin was detected using
Alexafluor 594-tagged phalloidin (4 U/ml) in 1% BSA in PBS for
2 h at RT. The cells were washed 3 times with 1% BSA in PBS,
and the tubulin antibody detected with FITC-conjugated donkey
anti-mouse antibody at 1:100 in 1% BSA in PBS for 1 h at RT.
The cells were then washed 3 times with PBS. The second PBS
wash contained 1 mg/ml Ho ¨echst 33342 to visualize DNA/
chromatin. The coverslips were mounted on slides using
Vectashield Hardset. Digital photomicrographs were captured
using Openlab Darkroom (Improvision) and a Retiga 1300 color
digital camera (Q Imaging).
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Differences between locostatin treated or untreated cells were
compared using a two-tailed unpaired Student’s t-test.
Supporting Information
Figure S1 Locostatin disrupts the mitotic spindle and chromo-
some organization. MEFs expressing (A) wild-type (RKIP+/+)o r
lacking RKIP (RKIP depleted or RKIP2/2) were plated at
26104 cells/coverslip and grown for 48 h before treatment with
either DMSO (Control) or locostatin (20 mM) for either 1 or 2 h.
Data represents the mean6S.E. percent abnormal mitotic spindles
(n=3), cells counted ranged from 33–119 for the various cell lines.
Found at: doi:10.1371/journal.pone.0006028.s001 (0.04 MB TIF)
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